~~<i id='140AC25BDD'><strike id='140AC25BDD'><tt id='140AC25BDD'><pre id='140AC25BDD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：fashion 2025-09-27 13:04:57 - browse：2

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： How to save health care price transparency rules

focus

leisure time

focus

leisure time

Wikipedia

explore

RubyWallauforSTATBiogenisjoiningtheindustry’sfervoroverimmuneandinflammatorydiseasedrugdevelopmentwi

WSS

As AI in medicine takes off, can 'human in the loop' prevent harm?

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Scrutiny of post

H5N1 virus can be tracked in retail milk, scientists say

Why depression after traumatic brain injury is distinct

UCLA team creates talking throat patch for voice disorders

knowledge

explore

focus

Bright Health sells Medicare Advantage business to Molina

Digital health: a case of mistaken identity

Drug repurposing or repositioning? The language matters

UCLA team creates talking throat patch for voice disorders

Peter Hotez and the public health issue of online harassment

Medicare coverage of Wegovy, once blocked, now looks possible

Walensky prepares to leave CDC — and Congress — behind

Making the case for fair compensation in clinical trials

Walensky prepares to leave CDC — and Congress — behind

Fentanyl is making it harder to start addiction treatment

leisure time

Liver decline slowed by off

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Pushing for an NIH office for post

Eyeing GLP

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Steward Health Care Massachusetts hospitals face fiscal disaster

focus

leisure time

Wikipedia

explore